Lilly to acquire Verve Therapeutics for $1 billion to advance one-time treatments for people with high cardiovascular risk
On Jun. 17, 2025, Eli Lilly and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular…